Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
Response’s ex-Sanofi asset hits goal in post-GLP-1 patients
Response shared phase 2 data, linking its asset to reductions in blood-fat levels and weight gain in post-GLP-1 patients.
Nick Paul Taylor
Aug 13, 2025 9:14am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
Novo Nordisk drops 2 obesity drugs during pipeline clearout
Aug 6, 2025 4:44am
Pfizer's embattled obesity program loses another GLP-1 drug
Aug 5, 2025 8:51am
Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing
Jul 30, 2025 7:35am
Fierce Pharma
Novo Nordisk names new CEO as it cuts sales, profit outlook
Jul 29, 2025 10:10am
